Eupraxia Pharmaceuticals Inc.
EPRXNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $453.62M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.25$9.32
- Volume (live)
- -
- Avg. volume (3M)
- 817.44K
Eupraxia Pharmaceuticals (EPRX) Stock Price & Financial Analysis
Eupraxia Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $6.70 - $7.00 |
|---|---|
| 52-Week High | $9.32 |
| 52-Week Low | $5.25 |
| Open | $6.81 |
| Volume (last close) | 540.29K |
| Average Volume (3M) | 817.44K |
| 50-Day MA | $7.52 |
|---|---|
| 200-Day MA | $7.34 |
| 1-Year Change | +33.63% |
| Market Cap | 453.62M |
|---|---|
| Shares Outstanding | 66.22M |
| Price to Book (P/B) | 3.46 |
| EV/EBITDA | -7.99 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Eupraxia Pharmaceuticals at a Glance
As of the Oct 26, 2026 close, Eupraxia Pharmaceuticals (EPRX) has a market capitalization of $453.62M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $52.43M in cash and securities against $2.00M of debt, a net cash position of $50.42M.
Eupraxia Pharmaceuticals does not currently pay a dividend.
The share price is up 33.6% over the past year. At $6.85 (the Oct 26, 2026 close) it sits within its 52-week range of $5.25 to $9.32, below its 200-day moving average of $7.34.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $17.00, 148.2% above the Oct 26, 2026 close.
Frequently Asked Questions About Eupraxia Pharmaceuticals
What is the current stock price for EPRX?
As of the Oct 26, 2026 close, EPRX stock trades at $6.85. The 52-week range is $5.25–$9.32, with a day range of $6.70–$7.00.
What is the P/E ratio for EPRX?
The P/E ratio (Price-to-Earnings) for EPRX is shown in the Key Statistics section. This valuation metric helps compare Eupraxia Pharmaceuticals Inc. to industry peers.
Does EPRX pay dividends?
Eupraxia Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for EPRX?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for EPRX is Buy. The average 12-month price target is $17.00, a 148.2% upside from the Oct 26, 2026 close of $6.85.
What is the market cap of EPRX?
As of the Oct 26, 2026 close, Eupraxia Pharmaceuticals's market capitalization is $453.6M, classifying it as a small-cap company. Eupraxia Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.